Myelodysplasia and Neurogenic Bladder Dysfunction Treatment & Management

  • Author: Terry F Favazza, MD; Chief Editor: Marc Cendron, MD   more...
 
Updated: Aug 26, 2010
 

Medical Care

Medical care of children with myelodysplasia who have a neurogenic bladder requires constant vigilance and adaptation to new problems. Therapy is based on a few basic goals: to ensure safe intravesical pressures, to prevent urinary stasis and UTIs, and to promote urinary continence. The ultimate goal of medical therapy is to preserve renal function. In older children, medication may help maintain continence.

  • Infection
    • UTIs are common in children with myelodysplasia. In the absence of reflux, patients with UTIs are treated symptomatically.
    • Patients with vesicoureteral reflux are often placed on prophylactic antibiotics to reduce the chance of upper UTI or pyelonephritis.
    • Bacteriuria is seen in as many as 55% of individuals who have received clean intermittent catheterization (CIC). Patients who are completely asymptomatic do not need treatment.
  • Reflux
    • Reflux occurs in 3-5% of infants with myelodysplasia and is usually associated with detrusor hyperreflexia or DSD.
    • Treatment consists of antibiotic prophylaxis to prevent infection, anticholinergic medications to lower detrusor filling and voiding pressures, and a method of bladder emptying, most commonly IC. In children with lower-grade reflux who empty their bladders completely, treatment may be limited to prophylactic antibiotics. In children with high-grade reflux, IC is started to ensure complete emptying.
    • Children unable to empty their bladders, regardless of reflux, are treated with CIC.
    • Children with detrusor hyperreflexia (with or without hydronephrosis) are started on anticholinergic therapy to decrease intravesical pressures and possibly decompress the upper GU tracts. Reflux treated in this manner has shown a dramatic response, resolving in 30-55% of children.
    • Avoid the Crede maneuver (voiding by suprapubic pressure) in children with reflux because it can increase pressures and aggravate the degree of reflux.
  • Intermittent catheterization
    • Because most patients with myelodysplasia are unable to spontaneously empty their bladders, numerous methods have been devised to potentiate bladder emptying. Initially, large numbers of patients underwent urinary diversion; however, frequency of renal failure was substantial. This changed dramatically with the introduction of CIC.
    • Bladder catheterization on a regular basis is a safe, effective method of emptying the bladder and, if performed under clean conditions, does not appear to significantly increase the risk of infection. More than any single concept, the practice of CIC has changed the treatment of and approaches to patients with neurogenic bladders.[3]
    • Currently, urinary diversion is rarely performed in pediatric patients.
  • Continence
    • Although not an issue in infancy, continence becomes more important as patients age. When children reach school age and social interactions increase, managing incontinence becomes more of a priority.
    • Medical therapy consists of anticholinergic medications to increase the functional bladder volume and to reduce involuntary contractions. Additionally, alpha agonists have been used infrequently in children to increase sphincter tone at the bladder neck.
  • Bowel function
    • Often, children with myelodysplasia have disturbances of bowel as well as urinary function. This is managed most commonly with mild laxatives, such as mineral oil, combined with enemas or digital stimulation to facilitate removal of bowel contents.
    • Constipation can affect bladder emptying adversely via a mechanism not yet fully understood but likely related to altered tone of the pelvic floor musculature or the physical compression of hard stool distorting the geometry of the bladder. The need for a program to combat constipation by maintaining soft stools and facilitating complete evacuation of bowel contents is an integral part of treatment in children with myelodysplasia.
Next

Surgical Care

Surgery for neurogenic bladder, although once performed on most patients, is now primarily reserved for patients who have progressive renal damage despite maximal medical therapy or for patients with a noncompliant bladder. Most procedures are designed to allow adequate low-pressure bladder storage (thereby protecting the upper GU tract), to correct persistent reflux and prevent renal scarring, or to aid with continence. Experimental intrauterine fetal surgery performed to limit future morbidity is under investigation at some centers.[4, 5, 6, 7]

  • Intrauterine surgery
    • Studies of surgically created neural tube defects in rats demonstrate that the exposed tissue in the myelomeningocele sustains secondary injury from mechanical and chemical factors during its prolonged exposure to the uterine environment. This has led to research on the effects of in utero closure of the defect.
    • Although considered experimental because of the limited numbers performed, preliminary findings appear to indicate that intrauterine closure can be accomplished with minimal morbidity to the fetus and the mother and that it may decrease the need for VP shunting later in life.
    • Whether in utero repair improves the neurologic outcome in these patients remains unclear.
  • Ureteral reimplantation
    • Uretal reimplantation can be performed in patients with recurrent symptomatic UTIs despite adequate bladder drainage and antibiotic prophylaxis or in patients with persistent high-grade reflux with demonstrated renal scarring.
    • The purpose of the procedure is to create a nonrefluxing connection between the ureter and the bladder.
    • Most often, the procedure is performed by tunneling the ureter beneath the detrusor muscle.
    • This treatment is very effective, provided that a regimen is implemented to ensure a low-pressure reservoir and bladder emptying.
  • Vesicostomy
    • In infants who cannot be catheterized or who demonstrate worsening renal function despite medical therapy and IC, cutaneous vesicostomy can be performed to establish adequate bladder drainage.
    • The bladder is brought out to the skin, and urine drains continually into a diaper.
    • Vesicostomy is an effective temporary procedure that may be reversed at any time.
  • Bladder augmentation
    • Bladder augmentation is an option in patients with small bladder capacity and poor bladder compliance despite maximal medical therapy.
    • By anastomosing a detubularized segment of bowel to the bladder, capacity can be increased and storage pressures can be lowered, minimizing upper GU tract deterioration and improving continence.
    • Depending on the segment of bowel used, problems with metabolic derangements, mucous production, stone formation, and hematuria can develop but usually respond to medical therapy.
    • If incontinence is a significant problem, a bladder neck sling procedure can be performed along with bladder augmentation.
  • Urinary diversion and undiversion
    • Formal urinary diversion for neurogenic bladder is very rarely performed today. The risks of major abdominal surgery, metabolic derangements, and long-term upper GU tract deterioration are present with urinary diversion.
    • Since the advent of CIC, some patients who underwent incontinent urinary diversion as infants have undergone successful undiversion with bladder augmentation.
Previous
Next

Consultations

Patients with myelodysplasia have a multitude of issues that require constant observation.

  • Intervention by a neurosurgeon is needed, starting at birth. Patients require initial closure of the spinal defect, CSF shunting, and monitoring for cord tethering or shunt malfunction.
  • Often, consultation with a neurologist is required to define defects and watch for any change in symptoms.
  • If significant bone abnormalities are present, consultation with an orthopedist may be necessary.
  • Parents, and eventually the child, undoubtedly need the support of a psychologist to help deal with the struggles inherent in raising a child or growing up with myelodysplasia.
  • Physical therapy may also be needed.
Previous
Next

Diet

Generally, dietary management is the first step to achieving fecal continence.

  • Constipation and diarrhea both need to be avoided. The goal is to provide enough bulk to have one bowel movement per day at a socially acceptable time. Usually, digital stimulation, suppositories, or enemas are used to regulate the timing of bowel movements.
  • Additionally, if the child has difficulty with constipation, altering the diet to include more fiber and the addition of bowel lubricants, such as mineral oil, may help regulate bowel movements. Adequate bowel and bladder management are crucial to optimizing social, school, and work activities.
  • In addition due to neurologic and orthopedic issues, mobility is limited, reducing the patient's ability to exercise. These patients are at high risk for obesity.
Previous
Next

Activity

Children with myelodysplasia often have limited development and/or motion of the extremities; however, no specific activity limitations are required. Children are encouraged to be as active as possible within the limitations of the defect.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

Terry F Favazza, MD  Physician, Urological Associates of Southern Arizona

Terry F Favazza, MD is a member of the following medical societies: American Urological Association, Arizona Medical Association, California Medical Association, Endourological Society, and Oregon Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Harry P Koo, MD  Chairman of Urology Division and Director of Pediatric Urology, Virginia Commonwealth University; Professor of Surgery, VCU School of Medicine, Medical College of Virginia; Director of Urology, Children's Hospital of Richmond

Harry P Koo, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, and American Urological Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Howard M Snyder III, MD  Professor, Department of Surgery, Division of Pediatric Urology, University of Pennsylvania School of Medicine

Howard M Snyder III, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Surgeons, American Medical Association, American Urological Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Martin David Bomalaski, MD, FAAP  Pediatric Urologist, Alpine Urology

Martin David Bomalaski, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, and American Urological Association

Disclosure: Nothing to disclose.

Daniel Rauch, MD, FAAP  Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine

Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine

Disclosure: Baxter Honoraria Consulting

Chief Editor

Marc Cendron, MD  Associate Professor of Surgery, Harvard School of Medicine; Consulting Staff, Department of Urological Surgery, Children's Hospital Boston

Marc Cendron, MD is a member of the following medical societies: American Academy of Pediatrics, American Urological Association, European Society for Paediatric Urology, Johns Hopkins Medical and Surgical Association, New Hampshire Medical Society, Society for Fetal Urology, and Society for Pediatric Urology

Disclosure: Nothing to disclose.

References
  1. Selzman AA, Elder JS, Mapstone TB. Urologic consequences of myelodysplasia and other congenital abnormalities of the spinal cord. Urol Clin North Am. Aug 1993;20(3):485-504. [Medline].

  2. Shaw GM, Velie EM, Wasserman CR. Risk for neural tube defect-affected pregnancies among women of Mexican descent and white women in California. Am J Public Health. Sep 1997;87(9):1467-71. [Medline].

  3. Kochakarn W, Ratana-Olarn K, Lertsithichai P, Roongreungsilp U. Follow-up of long-term treatment with clean intermittent catheterization for neurogenic bladder in children. Asian J Surg. Apr 2004;27(2):134-6. [Medline].

  4. Bruner JP, Tulipan N, Paschall RL, et al. Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus. JAMA. Nov 17 1999;282(19):1819-25. [Medline].

  5. Bruner JP, Richards WO, Tulipan NB, Arney TL. Endoscopic coverage of fetal myelomeningocele in utero. Am J Obstet Gynecol. Jan 1999;180(1 Pt 1):153-8. [Medline].

  6. Meuli M, Meuli-Simmen C, Hutchins GM, et al. In utero surgery rescues neurological function at birth in sheep with spina bifida. Nat Med. Apr 1995;1(4):342-7. [Medline].

  7. Tulipan N, Bruner JP. Myelomeningocele repair in utero: a report of three cases. Pediatr Neurosurg. Apr 1998;28(4):177-80. [Medline].

  8. Akbar M, Abel R, Seyler TM, et al. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. BJU Int. Sep 2007;100(3):639-45. [Medline].

  9. Riccabona M, Koen M, Schindler M, et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol. Feb 2004;171(2 Pt 1):845-8; discussion 848. [Medline].

  10. Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol. Jul 2003;44(1):139-43. [Medline].

  11. Altaweel W, Jednack R, Bilodeau C, Corcos J. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol. Mar 2006;175(3 Pt 1):1102-5. [Medline].

  12. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. Jul 2005;174(1):196-200. [Medline].

  13. Bauer SB. Voiding dysfunction in children: Neurogenic and non-neurogenic. In: Walsh PC, Wein AJ, Retik AB, Vaughan ED, eds. Campbell's Urology. Vol 3. 8th ed. WB Saunders Co; 2002:2231-2261.

  14. Bauer SB. The management of the myelodysplastic child: a paradigm shift. BJU Int. Oct 2003;92 Suppl 1:23-8. [Medline].

  15. Bellinger MF. Myelomeningocele and neuropathic bladder. In: Gillenwater JY, Howard SS, Grayhack JT, eds. Adult and Pediatric Urology. 3rd ed. Mosby-Year Book; 1996:2489-528.

  16. Carr MC. Prenatal management of urogenital disorders. Urol Clin North Am. Aug 2004;31(3):389-97, vii. [Medline].

  17. Elliott SP, Villar R, Duncan B. Bacteriuria management and urological evaluation of patients with spina bifida and neurogenic bladder: a multicenter survey. J Urol. Jan 2005;173(1):217-20. [Medline].

  18. Ellsworth P, Gormley EA, Cendron M. Urodynamic testing in the pediatric patient. In: American Urological Associate Update Series. Lesson 12. Vol 18. AUA; 1999:90-5.

  19. Hayashi Y, Yamataka A, Kaneyama K, et al. Review of 86 patients with myelodysplasia and neurogenic bladder who underwent sigmoidocolocystoplasty and were followed more than 10 years. J Urol. Oct 2006;176(4 Pt 2):1806-9. [Medline].

  20. Husmann DA. Occult spinal dysraphism (the tethered cord) and the urologist. In: American Urological Association Update Series. Lesson 10. Vol 14. AUA; 1995:78-83.

  21. Poppas D, Bauer S. Urologic evaluation of the myelodysplastic child. In: American Urological Association Update Series. Lesson 36. Vol 16. AUA; 1997:282-7.

  22. Sakakibara R, Hattori T, Uchiyama T, et al. Uroneurological assessment of spina bifida cystica and occulta. Neurourol Urodyn. 2003;22(4):328-34. [Medline].

  23. Snodgrass WT, Adams R. Initial urologic management of myelomeningocele. Urol Clin North Am. Aug 2004;31(3):427-34, viii. [Medline].

  24. Stone, AR. Neurourologic evaluation and urologic management of spinal dysraphism. Neurosurg Clin N Am. 1995;6(2):269-277. [Medline].

  25. Sutherland RS, Mevorach RA, Baskin LS, Kogan BA. Spinal dysraphism in children: an overview and an approach to prevent complications. Urology. Sep 1995;46(3):294-304. [Medline].

  26. Tarcan T, Bauer S, Olmedo E, et al. Long-term followup of newborns with myelodysplasia and normal urodynamic findings: Is followup necessary?. J Urol. Feb 2001;165(2):564-7. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.